Mode
Text Size
Log in / Sign up

Retrospective cohort shows ERT associated with lower mortality in Chinese late-onset Pompe disease patients.

Retrospective cohort shows ERT associated with lower mortality in Chinese late-onset Pompe disease p…
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider enzyme replacement therapy association with lower mortality in late-onset Pompe disease while noting survival bias limits causal inference.

This retrospective cohort study evaluated 68 Chinese patients with late-onset Pompe disease over a 17-year period at a single center. The study setting was a single center, and findings are exploratory. Participants were categorized into an enzyme replacement therapy group comprising 47 patients and a no enzyme replacement therapy group containing 21 patients.

The primary outcome of mortality rate showed 6.4% in the enzyme replacement therapy group versus 57.1% in the no enzyme replacement therapy group. Secondary outcomes indicated glycogenin accumulation appears earlier than autophagy marker in the observed population. Muscle pathology severity correlated with lower body mass index, shorter 6-min walk test, and spinal curvature abnormalities. The c.2238G > C (p.W746C) mutation was present in 43.3% of patients. Functional outcomes showed greater improvements in patients who initiated enzyme replacement therapy shortly after diagnosis compared to those who started later, based on an exploratory subgroup of n=10.

Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported. Key limitations include a small sample size in exploratory subgroup analysis and survival bias that limits causal inference. Findings are exploratory and require validation in larger studies.

Practice relevance is not reported. Clinicians must recognize that all findings should be interpreted as hypothesis-generating and preliminary.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionPompe disease is a muscular lysosomal storage disorder characterized by autosomal recessive inheritance and caused by deficiency of the acid alpha-glucosidase (GAA) enzyme. Late-onset Pompe disease (LOPD) exhibits heterogeneous clinical presentations, which are influenced by the type of GAA mutation and residual enzyme activity.MethodsIn this study, we conducted a retrospective analysis of 68 Chinese LOPD patients over a 17-year period at a single center to delineate the real-world disease status and survival outcomes.ResultsAmong the 47 patients who received enzyme replacement therapy (ERT), the mortality rate was 6.4%, compared to 57.1% in the 21 patients who did not receive ERT. Muscle pathology analysis revealed that glycogenin accumulation appears earlier than autophagy marker, but this finding is exploratory and requires validation in larger studies. The severity of muscle pathology correlated with lower body mass index (BMI), shorter 6-min walk test (6MWT) and spinal curvature abnormalities. The most frequent GAA gene mutation identified was c.2238G > C (p.W746C), present in 43.3% of patients. In an exploratory subgroup analysis (n = 10), patients who initiated ERT shortly after diagnosis exhibited greater improvements in muscle strength and 6MWT results compared to those who started treatment later; however, the small sample size precludes definitive conclusions.ConclusionIn summary, our exploratory findings hypothesize that glycogenin may be an early pathological marker, but this requires prospective validation. ERT was associated with higher survival probability in this cohort, although survival bias limits causal inference. Earlier ERT initiation showed an association with better functional outcomes in a small subgroup. Lower BMI, shorter 6MWT, and spinal curvature abnormalities correlated with more severe muscle pathology in univariate analyses. All findings should be interpreted as hypothesis-generating due to study limitations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.